Clinical Trials
75 trialsELEGANT
Stemline Therapeutics, Inc.
PIKALO-1
Eli Lilly and Company
ELEGANCE
Novartis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
CAMBRIA-1
AstraZeneca
IMPULSE
Novartis
SERENA-1
AstraZeneca
SERENA-6
AstraZeneca
PIKASSO-01
Eli Lilly and Company
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
EMBER-4
Eli Lilly and Company
OPERA-01
Olema Pharmaceuticals, Inc.
MONARCH plus
Eli Lilly and Company
MONARCH 3
Eli Lilly and Company
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Eli Lilly and Company
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
OVELIA
Tolmar Inc.
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
DB-08
AstraZeneca
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
AMALEE
Novartis
SERENA-4
AstraZeneca
EMERALD
Stemline Therapeutics, Inc.
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Arvinas Inc.
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
CAMBRIA-2
AstraZeneca
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RIGHT Choice
Novartis
TP-II
Palleos Healthcare GmbH
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
INGE-B
iOMEDICO AG
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
CheckMate 7A8
Bristol-Myers Squibb
PRECYCLE
Palleos Healthcare GmbH
neoMONARCH
Eli Lilly and Company
SALSA
AstraZeneca
FIRST
AstraZeneca
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
West-Ward Pharmaceutical
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
West-Ward Pharmaceutical
FACE
Novartis
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Merck Sharp & Dohme LLC
MINT
AstraZeneca